共 60 条
[1]
Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424
[2]
Ferlay J(2018)Treatment of patients with peritoneal metastases from gastric cancer Ann Gastroenterol Surg 2 116-123
[3]
Soerjomataram I(2021)Contribution of chemotherapy to improved prognosis in stage 4 gastric cancer: trend analysis of a regional population-based cancer registry in Japan Int J Clin Oncol 26 378-386
[4]
Kitayama J(2022)Changes in chemotherapeutic strategies and their prognostic impact in patients with advanced gastric cancer In Vivo 36 409-415
[5]
Ishigami H(2017)Intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis Gastric Cancer 20 111-121
[6]
Yamaguchi H(2018)Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial J Clin Oncol 36 1922-1929
[7]
Nakao T(2021)Intraperitoneal administration of paclitaxel combined with S-1 plus oxaliplatin as induction therapy for patients with advanced gastric cancer with peritoneal metastases Ann Surg Oncol 28 3863-3870
[8]
Kaneko R(2022)Outcomes of a phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases Ann Surg Oncol 29 8597-8605
[9]
Tanaka H(2022)Safety and efficacy of intraperitoneal paclitaxel plus intravenous fluorouracil, leucovorin, and oxaliplatin (FOLFOX) for gastric cancer with peritoneal metastasis Ann Surg Oncol 29 5084-5091
[10]
Arigami T(2014)Intraperitoneal paclitaxel induces regression of peritoneal metastasis partly by destruction of peripheral microvessels Cancer Chemother Pharmacol 73 605-612